AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
List view / Grid view
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
A survey has shown that the pharmaceutical industry believes R&D will see a lot of benefit from digital transformation and that AI will be at the forefront.
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The rapid growth of the Osteoarthritis can be attributed to the launch of new therapies priced at a substantial premium to small-molecule therapies...
15 June 2016 | By Victoria White, Digital Content Producer
The development of a vaccine against the Zika virus should be viewed in the context of tackling all mosquito-borne diseases, according to GlobalData...
16 February 2016 | By Victoria White
A GlobalData analyst says that while a Zika virus vaccine could be an effective measure in the long term, it remains several years away...
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
28 January 2015 | By GlobalData
While current treatments for Alzheimer’s Disease are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData...